BSL5 170327

Drug Profile

BSL5 170327

Alternative Names: BSL5-170327C; BSL5-170327S

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kao Corporation
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Skin disorders

Most Recent Events

  • 27 Oct 2017 Kao Corporation completes a phase I trial in Skin disorders (In volunteers) in Japan (Topical) (UMIN000027155)
  • 19 May 2017 Phase-I clinical trials in Skin disorders (In volunteers) in Japan (Topical) (UMIN000027155)
  • 17 May 2017 Kao Corporation plans a phase I trial In volunteers in Japan (Topical) (UMIN000027155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top